Company news
Royalty Pharma Plc (NASDAQ:RPRX) news
Royalty Pharma Plc news releases on 6ix. Latest, Jul 18, 2025: Royalty Pharma Declares Third Quarter 2025 Dividend
Press releases — page 2
Royalty Pharma Declares Third Quarter 2025 Dividend
July 17, 2025
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 16, 2025
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 15, 2025
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
June 23, 2025
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025
Royalty Pharma Completes the Acquisition of Its External Manager
May 15, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 11, 2025
Royalty Pharma Reports First Quarter 2025 Results
May 7, 2025
Royalty Pharma Declares Second Quarter 2025 Dividend
April 20, 2025
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
April 16, 2025
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
April 7, 2025
Royalty Pharma Announces Upcoming Investor Day
March 26, 2025
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
Royalty Pharma Announces R&D Funding Collaboration With Biogen
February 11, 2025
Royalty Pharma Reports Q4 and Full Year 2024 Results
February 10, 2025
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
January 28, 2025
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
January 27, 2025
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
January 9, 2025
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
November 13, 2024
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
November 6, 2024
Royalty Pharma Reports Third Quarter 2024 Results
November 5, 2024
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
November 3, 2024
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
November 3, 2024
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 15, 2024
Royalty Pharma Declares Fourth Quarter 2024 Dividend
October 10, 2024
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
September 2, 2024
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
August 27, 2024
Royalty Pharma Reports Second Quarter 2024 Results
August 7, 2024
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 23, 2024
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
Royalty Pharma Declares Third Quarter 2024 Dividend
July 16, 2024
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 3, 2024
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
June 2, 2024
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 27, 2024
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 21, 2024
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 8, 2024
Royalty Pharma Reports First Quarter 2024 Results
May 8, 2024
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
April 18, 2024
Royalty Pharma Declares Second Quarter 2024 Dividend
April 16, 2024
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
February 27, 2024
Royalty Pharma Reports Q4 and Full Year 2023 Results
February 14, 2024
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 29, 2024
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 7, 2024
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 26, 2023
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 12, 2023
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 12, 2023
Royalty Pharma Reports Third Quarter 2023 Results
November 7, 2023
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 18, 2023
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 15, 2023